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The human DEAD box protein 3 (DDX3) has been implicated in different processes contributing to gene expression. Interest-
ingly, DDX3 is required as an essential host factor for the replication of HIV and hepatitis C virus (HCV) and is therefore consid-
ered a potential drug target. On the other hand, DDX3 interacts with IB kinase  (IKK) and TANK-binding kinase 1 (TBK1)
and contributes to the induction of antiviral type I interferons (IFNs). However, the molecular mechanism by which DDX3 con-
tributes to IFN induction remains unclear. Here we show that DDX3mediates phosphorylation of interferon regulatory factor 3
(IRF3) by the kinase IKK. DDX3 directly interacts with IKK and enhances its autophosphorylation and activation. IKK then
phosphorylates several serine residues in the N terminus of DDX3. Phosphorylation of DDX3 at serine 102 (S102) is required for
recruitment of IRF3 to DDX3, facilitating its phosphorylation by IKK. Mutation of S102 to alanine disrupted the interaction
between DDX3 and IRF3 but not that between DDX3 and IKK. The S102Amutation failed to enhance ifnb promoter activation,
suggesting that the DDX3-IRF3 interaction is crucial for this effect. Our data implicates DDX3 as a scaffolding adaptor that di-
rectly facilitates phosphorylation of IRF3 by IKK. DDX3might thus be involved in pathway-specific activation of IRF3.
The human DEAD box RNA helicase DDX3 is a multifunctionalcellular protein which has been implicated in various pro-
cesses linked to gene expression (1). Its RNA helicase activity is
coopted by viruses that require DDX3 as an essential host factor
for their replication, such as HIV and HCV (2–4). In contrast, we
and others have previously demonstrated that DDX3 contributes
to antiviral innate immune signaling pathways leading to ifnb in-
duction (5–9). This function of DDX3 is independent of its
ATPase and helicase activity (6, 7). ifnb promoter induction re-
quires activation of the transcription factors IRF3 and IRF7, which
occurs only downstream of certain, mostly antiviral, pattern rec-
ognition receptors (PRRs). Antiviral PRRs comprise the endo-
somal Toll-like receptors TLR3, TLR7, TLR8, and TLR9, cytosolic
RIG-like helicases (RLHs), and several newly discovered cytosolic
DNA receptors (10). These receptors recognize different species of
viral nucleic acids and induce type I IFNs in response (11). TLR3
and TLR4 engage the TRIF (TIR domain-containing adaptor in-
ducing IFN-)-dependent pathway for activation of IRF3 (12). In
this pathway, phosphorylation-dependent activation of IRF3 is
mediated by the IKK-related kinases TBK1 and IKKε (13, 14). The
RLHs also utilize TBK1 and IKKε for IRF3 activation after engag-
ing the adaptor molecule MAVS (mitochondrial antiviral signal-
ing) (15, 16). DNA receptors activate IRF3 through TBK1 and the
adaptor molecule STING (stimulator of IFN genes).
While these signaling pathways converge on IKKε and TBK1
for IRF3 activation, not all receptors that activate IKKε and/or
TBK1 lead to IRF3 activation (17). This suggests that additional
factors are required for linking the activated kinases to their sub-
strate IRF3.
We previously showed that DDX3 interacts with IKKε follow-
ing activation of the RIG-I (retinoic acid-inducible) pathway and
that it contributes to ifnb promoter induction downstream of
PRRs that utilize IKKε and TBK1 for IRF3 activation (6). Soulat et
al. published similar results regarding a role for DDX3 in ifnb
induction and demonstrated that DDX3 interacts with and is
phosphorylated by TBK1 (7). They also showed binding of DDX3
to the ifnbpromoter and hypothesized that phosphorylated DDX3
directly mediates ifnb transcription (7). Interestingly, the function
of DDX3 in ifnb induction is targeted by viral immune evasion
strategies that inhibit the induction of this potent antiviral cyto-
kine. For example, we previously showed that the vaccinia virus
(VACV) protein K7 antagonizes DDX3 by binding to its N-termi-
nal tail region, which is required for ifnb promoter induction (6,
18, 19). The hepatitis B virus (HBV) polymerase (Pol) is another
viral protein that interacts with DDX3. Initially it was shown that
DDX3 gets incorporated into the viral nucleocapsid and blocks
viral replication (20). More recently, it was demonstrated that
HBV Pol targets DDX3 in much the same way as K7: it blocks its
interaction with IKKε/TBK1 and consequently inhibits IRF3 acti-
vation and ifnb induction (8, 9). Another recent study also con-
firmed a role for DDX3 in ifnb induction but placed DDX3 further
upstream in the signaling pathway. Oshiumi et al. suggested that
DDX3 directly senses HCV RNA and then triggers MAVS-depen-
dent signaling (5). In a follow-up study, those authors also sug-
gested that the HCV core protein, which had previously been
shown to interact with DDX3 (21–23), blocks the interaction be-
tween DDX3 and MAVS and thereby prevents initiation of this
pathway (24). In summary, there is now strong evidence that hu-
man DDX3 contributes to ifnb promoter induction, in particular
with respect to the RIG-I pathway. However, its exact placement
in the signaling pathway and its mechanism of action are still
unclear. Several studies, including ours, placed DDX3 down-
stream of TBK1/IKKε (6–9). However, Oshiumi et al. placed it
upstream of MAVS, as a viral RNA sensor that functions in con-
junction with RIG-I/MAVS (5, 24). It is also unclear whether the
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effect of DDX3 is located upstream of IRF3 activation and/or
whether it binds directly to the ifnb promoter to enhance tran-
scription (6, 7). The present study therefore aimed at placing
DDX3 more firmly in the signaling pathway(s) leading to ifnb
induction by dissecting its molecular interaction with IKKε and
the functional consequences of this interaction. We show here
that DDX3 mediates IKKε activation and then couples the active
kinase to its substrate, the transcription factor IRF3. Mechanisti-
cally, DDX3 therefore acts as a downstream scaffolding adaptor
that links IKKε and IRF3.
MATERIALS AND METHODS
Plasmids, recombinant proteins, and antibodies. The expression con-
structs pCMV-HA-DDX3, pCMV-Myc-DDX3, pHis-DDX3, HA-K7,
and His-K7 were described in our previous study (6). pCMV-HA-DDX3
and pHis-Parallel2-DDX3 point mutations were introduced by following
the instructions for the QuikChange site-directed mutagenesis kit (Agi-
lent), except that Pfusion HiFi polymerase was used (New England Bio-
Labs). TBK1-Flag, IKKε-Flag, IKKε KD-Flag (kinase dead, K48A), and
IRF3-Flag were kind gifts from Kate Fitzgerald (University of Massachu-
setts Medical School, Worcester, MA). IKKε-Flag truncation constructs
were generated by amplifying the relevant sequences by PCR from IKKε-
Flag and inserting them into pFlag-CMV2 (Sigma-Aldrich).
DDX3(1– 408) (a DDX3 construct consisting of amino acids [aa] 1 to
408), DDX3(409 – 662), DDX3(139 – 408), and DDX3(1–139) were de-
scribed previously (6). DDX3(80 – 408), DDX3(100 – 408), DDX3(110 –
408), DDX3(120 – 408), and DDX3(130 – 408) were constructed by am-
plifying the relevant sequences by PCR from pCMV-HA-DDX3 and
inserting them into pHisparallel2 or pCMV-HA vectors. Full-length
DDX3 was subcloned from pHis-DDX3 into pGSTParallel2 using the
EcoRI and SalI restriction sites to generate the bacterial expression con-
struct pGST-DDX3. pHis-Rab14 and DDX3(5–172) constructs were kind
gifts from Amir Khan (Trinity College Dublin). Glutathione S-transferase
(GST)–IRF3 (aa 380 to 427) peptides and constructs were kindly provided
by John Hiscott and Qiang Sun (McGill University, Montreal, Canada). A
construct for full-length His-IRF3 was provided by Marion Butler (NUI
Maynooth). Purified recombinant protein kinase GST-IKKε was pur-
chased from Proqinase (Freiburg, Germany). The antibodies used were
anti-Flag M2 monoclonal antibody (MAb) (Sigma-Aldrich), anti-Myc
MAb clone 9E10 (Sigma-Aldrich), antihemagglutinin (anti-HA) MAb
(Covance), anti-DDX3 (Santa Cruz or Bethyl Laboratories), anti-IKKε
(Abcam, Cambridge, United Kingdom), anti-IRF3 (IBL), anti-phospho-
Ser396-IRF3 (Cell Signaling Technology), anti-phospho-Ser172-TBK1/
IKKε and anti-phospho-Ser172 IKKε (Cell Signaling Technology), anti-
His (Sigma-Aldrich), and anti-GST (Promega).
Cell culture and transfection. HEK293T and A549 cells were main-
tained in Dulbecco’s modified Eagle medium (DMEM) with Glutamax
(Gibco), supplemented with 10% fetal calf serum and 50 ng/ml gentami-
cin (Sigma-Aldrich). Transient DNA transfections for immunoprecipita-
tions and pulldowns were performed using the calcium phosphate
method. The total amount of DNA was kept constant by addition of
empty vector.
siRNA knockdown of DDX3. For small interfering RNA (siRNA)
knockdown of endogenous human DDX3, two different stealth RNA in-
terference (RNAi) oligonucleotides, DDX3-1 (GGGAGAAAUUAUCAU
GGGAAACAUU) (HSS102712; Invitrogen) and DDX3-2 (UUCAACAA
GAAGAUCCAACAAAUCC) (HSS102713; Invitrogen), with a control
oligonucleotide of matched GC content (all supplied by Invitrogen), were
used. Approximately 60,000 HEK293T cells were transfected with RNAi
(50 pmol) in individual wells of a 24-well plate using Lipofectamine 2000
(Invitrogen), according to the manufacturer’s instructions. At 48 h after
transfection, cell lysates were prepared and analyzed by SDS-PAGE and
immunoblotting.
GST or His pulldown assays. Bacterial expression constructs for His-
or GST-tagged proteins were transformed into Escherichia coli
BL21(DE3). Protein expression was induced by IPTG (isopropyl--D-
thiogalactopyranoside), and recombinant proteins were purified using
either nickel-agarose or glutathione-Sepharose (both from Chromatrin
Ltd., Dublin, Ireland). For pulldowns, equal amounts of the different His-
or GST-tagged fusion proteins were used, as estimated by SDS-PAGE and
Coomassie staining prior to use. Cell lysates containing Flag-tagged pro-
tein expressed in HEK293T cells, 0.1 g of GST-IKKε, or 0.5 g of puri-
fied recombinant protein were incubated with relevant purified His- or
GST-tagged proteins immobilized on nickel-agarose or glutathione-Sep-
harose, respectively. Protein complexes were precipitated and washed
thoroughly before being subjected to SDS-PAGE and Western blot anal-
ysis.
Coimmunoprecipitation assays. Coimmunoprecipitations were per-
formed from cell lysates of transiently transfected HEK293T or A549 cells,
which were harvested 24 h after transfection. Cells were lysed in immu-
noprecipitation (IP) lysis buffer (50 mM HEPES [pH 7.4], 150 mM NaCl,
2 mM EDTA, 1% NP-40, 10% glycerol, 10 mM NaF, 1 mM sodium or-
thovanadate, protease inhibitors). Cell lysates were incubated with 20 l
of Flag-M2 agarose (Sigma-Aldrich) or protein A/G agarose (Santa Cruz)
that had been precoupled with relevant antibodies at 4°C overnight and
blocked with 5% bovine serum albumin (BSA). The immunoprecipitated
protein complexes were washed thoroughly and then eluted by boiling in
Laemmli sample buffer before being subjected to SDS-PAGE and Western
blot analysis.
In vitro kinase assays. In vitro kinase assays were carried out either
with Flag-tagged IKKε or TBK1 immunoprecipitated from lysates of
transfected HEK293T cells or with 55 ng of purified recombinant GST-
IKKε (Proqinase). These were incubated with recombinant substrates in
kinase assay buffer (50 mM HEPES [pH 7.5], 5 mM glycerophosphate, 2
mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2) in the presence of 20
M unlabeled ATP for 30 min at 30°C. Samples were analyzed by SDS-
PAGE and Western blot analysis with relevant antibodies. Alternatively,
kinase assays were carried out in the presence of 10 M unlabeled ATP
and 5Ci of [-32P]ATP. Samples were then analyzed by SDS-PAGE and
autoradiography.
Determination of phosphorylation sites by mass spectrometry. 0.5
g of His-DDX3 (full-length) or His-DDX3 (1 to 408) were phosphory-
lated in vitro using recombinant protein kinase GST-IKKε as described
above. Samples were then subjected to SDS-PAGE and Coomassie stain-
ing. Bands that corresponded to His-DDX3 (full length)- and His-
DDX3(1– 408)-specific bands were cut out and reductively alkylated in-
gel with 10 mM dithiothreitol (DTT) and 50 mM iodoacetamide. Gel
bands were then digested with trypsin solution (20 l of 12.5 g/ml tryp-
sin [Roche] in 20 mM ammonium bicarbonate) overnight. The digested
peptides were extracted, dried in a speed vac, and suspended in 50 l of
1% formic acid. A 15-l portion of the peptide extract was injected onto a
Dionex U3000 nanoLC system with a 75-m by 15-cm C18 PepMap col-
umn using a 65-min linear gradient from 5 to 35% B (90% acetonitrile in
0.1% formic acid). The instrument method used was a TOP 15 method
(MS survey scan followed by 15 ion trap tandem mass spectrometry [IT-
MSMS] scans) with multistage activation (MSA). Data were extracted
with Proteome Discoverer (v. 1.3), and database searching was done using
the Mascot search engine (v. 2.3.2).
Reporter gene assays. ifnb promoter induction was measured in
HEK293T cells seeded into 96-well plates (2  104 cells per well) and
transfected 24 h later with expression vectors and luciferase reporter gene
constructs, using GeneJuice (Merck/Millipore). Sixty nanograms of an
ifnb promoter firefly luciferase reporter gene construct was used in con-
junction with 20 ng of a pGL3-Renilla luciferase construct (both provided
by Andrew Bowie, Trinity College Dublin). The total amount of DNA
transfected was kept constant at 230 ng/well by addition of matching
empty vector DNA. Firefly andRenilla luciferase activity was measured 24
h after transfection. Renilla luciferase readings were used to normalize for
transfection efficiency. Data are expressed as mean fold induction stan-
dard deviations (SD) relative to control levels for an individual experi-
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ment performed in triplicate. Remaining cell lysates from each triplicate
were pooled and subjected to SDS-PAGE and Western blot analysis to
show expression levels of transfected DDX3 and IKKε.
Data representation and statistical analysis. All data shown are rep-
resentative of at least two independent repeat experiments, and most are
representative of 3 to 5 repeat experiments. Luciferase reporter gene assays
are representative of at least 3 independent repeat experiments.
Statistical analysis was carried out using a two-tailed unpaired Stu-
dent’s t test and SPSS software.
RESULTS
DDX3enhances activationof IKK and IRF3.First, we wanted to
confirm whether DDX3 affects activation of IRF3 or whether it
exerts its effect downstream of or in parallel with IRF3. We had
previously shown that DDX3 knockdown affects an IRF3 transac-
tivation assay based on a GAL4-IRF3 fusion protein used in con-
junction with a GAL4-dependent reporter construct (6). VACV
K7 and HBV Pol, both of which target DDX3, have been shown to
inhibit IRF3 activation, which provides indirect evidence for in-
volvement of DDX3 in IRF3 activation (6, 8, 9). However, it has
also been suggested that DDX3 binds directly to the ifnb promoter
and has no interaction with IRF3 (7). In order to test for an effect
of DDX3 on IKKε and IRF3 activation, we used small interfering
RNA (siRNA) to knock down endogenous human DDX3. Flag-
IKKε was then expressed in these cells, followed by immunopre-
cipitation and in vitro kinase assays with recombinant glutathione-S-
transferase (GST)-IRF3 (aa 380 to 427). DDX3 knockdown with
two different siRNA oligonucleotides led to a clear reduction of
IKKε-induced phosphorylation of IRF3 at serine 396 (Fig. 1A).
S396 is one of the key phosphorylation sites for IKKε/TBK1 and is
required for IRF3 activation (25). This finding suggested that
IKKε activation or activity is decreased in the absence of DDX3.
Consistent with this, the addition of recombinant DDX3 en-
hanced IKKε-mediated S396 phosphorylation of IRF3 in kinase
assays with recombinant IKKε (Fig. 1B). We also noticed that the
presence of DDX3 induced a higher-molecular-weight form of
IKKε (Fig. 1B, asterisk), which likely represents a phosphorylated
form of IKKε. We therefore tested whether DDX3 enhances phos-
phorylation of IKKε at serine 172. S172 is located in the activation
loop of IKKε and required for its activation (26). Indeed, S172
phosphorylation of IKKε was enhanced in the presence of DDX3
(Fig. 1C, top, lanes 2 and 4). DDX3 also enhanced IKKε-mediated
IRF3 phosphorylation in the same experiment (Fig. 1C, third
panel, lane 4), likely as a consequence of increased IKKε activity.
When DDX3 was coexpressed in HEK293 cells with small
amounts of exogenous IKKε, DDX3 also enhanced IKKε and IRF3
phosphorylation (Fig. 1D). Furthermore, exogenous expression
of DDX3 enhanced Sendai virus (SeV)-induced phosphorylation
of IRF3 (Fig. 1E). Finally, we wanted to confirm that endogenous
DDX3 is required for activation of endogenous IKKε and IRF3
following SeV stimulation. HEK293 cells have low levels of endog-
enous IKKε, and we therefore knocked down DDX3 expression in
the human lung epithelial cell line A549. In A549 cells with DDX3
knockdown, S396 phosphorylation of IRF3 was reduced com-
pared to that in cells treated with a control siRNA oligonucleotide
(NC) (Fig. 1F, fifth panel). In experiments with recombinant or
overexpressed IKKε (Fig. 1A to E), we used an antibody that rec-
ognizes pS172 in both TBK1 and IKKε. With the same antibody,
we observed a clear reduction of endogenous pS172 TBK1/IKKε
phosphorylation in cells treated with DDX3 siRNA (Fig. 1F, sec-
ond panel). In addition, we used a newer antibody that is more
specific for phosphorylated IKKε and saw a similar reduction in
pS172 IKKε levels in DDX3 knockdown cells (Fig. 1F, third
panel). As DDX3 also interacts with TBK1 (7), it is possible that
DDX3 affects both TBK1 and IKKε activation. Our study focused
on IKKε activation (because in our hands it is the stronger binding
partner for DDX3), and we carried out a combination of experi-
ments with recombinant, overexpressed, and endogenous IKKε.
Our results clearly demonstrate that DDX3 acts at the level of
IKKε and IRF3 by enhancing autophosphorylation of IKKε and
(consequently) IRF3 phosphorylation.
DDX3 directly interacts with the scaffolding/dimerization
domain of IKK. The in vitro kinase assays whose results are
shown in Fig. 1B and C were carried out with recombinant IKKε
and DDX3, suggesting that DDX3 directly interacts with IKKε.
We next carried out pulldown assays to confirm this and to map
their interaction. The recombinant His-tagged DDX3 proteins we
used for this analysis were the full-length protein (aa 1 to 662), the
N-terminal domain (aa 1 to 408), the C-terminal domain (aa 409
to 662), and the N-terminal domain with a truncated N-terminal
tail (aa 139 to 408). The 1– 408 and 409 – 662 constructs split
DDX3 at the linker region between its two RecA-like globular
domains (27). We have previously shown that the flexible N-ter-
minal tail region (aa 1 to 139) is required for the effect of DDX3 on
the ifnb promoter (6), which is why we included the 139 – 408
truncation mutant.
Full-length recombinant His-DDX3, as well as its N-terminal
(aa 1 to 408) and C-terminal (aa 409 to 662) domains, pulled
down GST-tagged recombinant IKKε, confirming the direct in-
teraction and suggesting that DDX3 contains at least two distinct
interaction sites for IKKε (Fig. 2A). Interestingly, the 139 – 408
truncation of DDX3 did not interact with IKKε (Fig. 2A), indicat-
ing that the IKKε interaction is at least partially mediated by res-
idues in the flexible N-terminal region of DDX3 that is required
for ifnb promoter induction.
In Fig. 1, we have demonstrated that DDX3 enhances IKKε
autoactivation. Other adaptor proteins that contribute to IKKε
and TBK1 activation in cells are NAP1 (NAK-associated protein
1), TANK (TRAF family member-associated NF-B activator)
and Sintbad (similar to NAP1 TBK1 adaptor) (28), which have
recently been shown to bind to the C-terminal region of IKKε (aa
684 to 716) and the corresponding region in TBK1 (29, 30). We
therefore asked whether DDX3 interacts with IKKε in a similar
manner. We transfected HEK293T cells with constructs for Myc-
tagged DDX3 and a range of different Flag-tagged IKKε trunca-
tion mutants, followed by immunoprecipitation with an anti-Flag
antibody. DDX3 interacted strongly with a truncated IKKε con-
struct lacking the kinase and ubiquitin-like domains (aa 383 to
716), as well as constructs lacking the adaptor-binding region (aa
1 to 684 and 1 to 647) (Fig. 2B). DDX3 weakly interacted with a
truncated IKKε containing the kinase and ubiquitin-like domains
only (aa 1 to 383). We also performed a semiendogenous co-IP by
transfecting HEK293T cells with truncated IKKε constructs, fol-
lowed by immunoprecipitation of endogenous DDX3. Again,
DDX3 interacted with all truncated IKKε constructs but only
weakly with the 1-383 construct (Fig. 2C). We did not observe
consistent differences in binding between the other IKKε trunca-
tions, suggesting that DDX3 binds mainly to a region between aa
383 and 647 in IKKε, which corresponds to its scaffolding/
dimerization domain (SDD). The adaptor binding region (aa 684
to 716) was not required for DDX3 binding.
Gu et al.
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While the kinase and ubiquitin-like domains of IKKε are also
not required for the interaction, DDX3 binds to this region
weakly, presumably as a substrate for IKKε’s kinase activity.
The N terminus of DDX3 is phosphorylated by IKK. There
is evidence that interaction with IKKε leads to phosphorylation of
DDX3. Soulat et al. described DDX3 as a phosphorylation target
of TBK1 (7), and we also observed the appearance of higher-mo-
lecular-weight forms of DDX3 after coexpression of DDX3 with
IKKε but not with a kinase-inactive mutant of IKKε (6) (Fig. 3A).
We carried out in vitro kinase assays with IKKε and recombinant
DDX3 in order to confirm that DDX3 is a substrate of IKKε.
Recombinant DDX3 was phosphorylated in vitro by recombinant
IKKε (Fig. 3B). This phosphorylation was comparable in intensity
to that of the bona fide IKKε substrate IRF3 in the same experi-
ment (Fig. 3B). Because the N- and C-terminal domains of DDX3
both directly interacted with IKKε (Fig. 2A), we asked whether
both domains are phosphorylated by IKKε. While we observed a
very weak phosphorylation signal for the C-terminal domain of
DDX3 (aa 409 to 662), the N-terminal domain (aa 1 to 408) was
phosphorylated much more strongly (Fig. 3C). The N-terminal
FIG 1 DDX3 enhances activation of IKKε and IRF3. (A) HEK293T cells were transfected with siRNAs against DDX3 (DDX3-1 and DDX3-2) or a negative-
control oligonucleotide (NC). After 24 h, cells were transfected with a plasmid vector for Flag-IKKε or with an empty vector. Flag-IKKεwas immunoprecipitated,
and in vitro kinase assays were performed using recombinant GST-IRF3 (aa 380 to 427) as a substrate. IRF3 phosphorylation was detected with a phospho-specific
antibody against serine 396 by Western blot (WB) analysis. (B and C) In vitro kinase assays were carried out with recombinant GST-IKKε and IRF3. Recombinant
His-DDX3 was added where indicated. Phosphorylation of IKKε and IRF3 was detected with phospho-specific antibodies against S172 in IKKε and S396 in IRF3.
The asterisk indicates a higher-molecular-weight band of IKKε. (D and E) HEK293T cells were transfected with expression constructs for myc-DDX3 and
Flag-IRF3. (D) Cells were cotransfected with a Flag-IKKε construct or empty vector. (E) Cells were stimulated with SeV 24 h after transfection for the indicated
length of time. (F) A549 cells were transfected with an siRNA oligonucleotide against DDX3 (DDX3-2) or a negative-control oligonucleotide (NC). After 48 h,
cells were stimulated with SeV for the indicated length of time. Cell lysates were subjected to SDS-PAGE and WB analysis.
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truncation mutant DDX3(139 – 408) failed to interact with IKKε
(Fig. 2A), which suggested that the phosphorylation sites for IKKε
might be contained in the N-terminal tail region. Therefore, we
next used the isolated N-terminal region of DDX3 as a substrate.
Polypeptides comprising aa 1 to 139 or aa 5 to 172 of DDX3 were
strongly phosphorylated by IKKε in kinase assays, suggesting that
this region indeed contains phosphorylation sites for IKKε (Fig.
3D and E). An unrelated His-tagged protein of a similar molecular
weight (Rab14) served as a control and was not phosphorylated by
IKKε (Fig. 3D). TBK1 appeared to phosphorylate the N-terminal
domain of DDX3 to an extent similar to that exhibited by IKKε, as
evidenced by the shift of DDX3(5–172) after nonradioactive ki-
nase assays with immunoprecipitated IKKε or TBK1 (Fig. 3E).
Mapping of IKK phosphorylation sites in DDX3. We next
aimed at identifying the exact residues in DDX3 that are phos-
phorylation sites for IKKε. This was not a trivial task, considering
that the N terminus of DDX3 (aa 1 to 172) contains 29 serine
residues and the C-terminal SG-rich domain (aa 580 to 662) con-
tains 20 serine residues, many of them arranged in clusters that are
potential targets for IKKε phosphorylation.
Hutti et al. recently defined an IKKε consensus phosphoryla-
tion motif, which they generated using a positional scanning pep-
tide library assay (31). Those authors kindly provided us with their
Scansite matrix (31), which we used to scan the DDX3 protein
sequence for IKKε consensus motifs (32). This revealed a large
number of potential, if suboptimal, IKKε phosphorylation sites,
mainly clustered in the N- and C-terminal serine-rich regions of
DDX3. Due to our experimental evidence that the N-terminal tail
region of DDX3 (aa 5 to 172) is strongly phosphorylated by IKKε,
we focused on this region. Within this region, serine S71 had the
best Scansite score (0.7571), followed by S82, S57, S70, S137, S58,
S86, S23, S61, S152, S74, S28, S131, S62, S83, and S102 (1.1486).
Of these, S82, S57, S86, S61, S152, S74, S28, S131, S62, S83, and
S102 were also predicted to be phosphorylated by NetPhos 2.0
(score  0.75) (33). Due to this large number of potential phos-
phorylation sites, we carried out phosphorylation site mapping by
mass spectrometry. For this analysis, we used full-length DDX3
and DDX3(1– 408) that had been phosphorylated in vitro using
recombinant IKKε. We separated the phosphorylated protein by
SDS-PAGE and carried out a tryptic digest of the protein band,
followed by analysis of the tryptic peptides by ion trap mass spec-
trometry (IT-MS). For full-length DDX3, the only significant hit
we obtained was a phosphorylated peptide containing S70, S71,
and S74. For DDX3(1– 408), we obtained hits that matched
phosphorylation sites at S152, at S70, S71, or S74, at S102 or
S109, and at S82, S83, or S86 (Table 1). Based on these data and
the Scansite predictions, we selected S71, S82, S83, S102, and
S152 for serine-to-alanine substitution mutations. We gener-
ated single-alanine-substitution mutants for S71, S102, and
S152, a double-alanine mutant for S82 and S83 (2A mutant), a
triple-alanine mutant for S82, S83, and S102 (3A mutant), and
a quadruple-alanine mutant for S71, S82, S83, and S102 (4A
mutant). In kinase assays with IKKε, our single-alanine mu-
tants displayed reductions in phosphorylation between 	32%
for the S102A mutant and 	60% for the S71A and S152A mu-
tants. For the 2A mutant, phosphorylation was reduced by
	50%, and the 3A and 4A mutants retained only 	35% of
phosphorylation compared to the wild-type 1-408 truncation
construct (Fig. 4A). These data suggest that the serine residues
we identified are indeed phosphorylated by IKKε; however,
FIG 2 DDX3 directly interacts with the SDD domain of IKKε. (A) Purified
recombinant full-length His-DDX3 or the indicated His-DDX3 truncation
mutants were incubated with recombinant GST-IKKε. Following pulldown
with nickel (Ni)-agarose, interacting proteins were subjected to SDS-PAGE
and WB analysis. (B and C) HEK293T cells were transfected with constructs
for Flag-IKKε or the indicated Flag-IKKε truncation mutants and Myc-DDX3
(panel B only). Cell lysates were subjected to immunoprecipitation (IP) with
an anti-Flag (B) or anti-DDX3 (C) antibody, followed by SDS-PAGE and WB
analysis. Asterisks mark bands of the correct molecular weight for the IKKε
truncations (B). HC, antibody heavy chain band (C).
Gu et al.
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none of our alanine substitution mutants displayed a complete
loss of phosphorylation. We therefore also generated addi-
tional truncation mutants to narrow down the region contain-
ing the main phosphorylation site(s) for IKKε. In kinase assays
with IKKε, the 80-408 and 100-408 truncation mutants re-
tained strong phosphorylation (even though their phosphory-
lation was reduced by	15% and	37% compared to the 1-408
mutant), while constructs consisting of aa 110 onwards were
not phosphorylated by IKKε (Fig. 4B). These data pinpointed
the region between aa 100 and 110 as a major target site for
IKKε. This region of DDX3 contains two serine residues, S102
and S109. Interestingly, S102 was predicted to be phosphory-
lated by both the IKKε Scansite matrix and Netphos. Our mass
spectrometry results and the alanine substitution mutants also
confirmed that S102 is likely an IKKε phosphorylation target.
We therefore decided to mutate S102 to alanine in the context
of the 80-408 truncation mutant. This 80-408 S102A mutant
nearly completely lost phosphorylation by IKKε (Fig. 4C), sug-
gesting that S102 accounts for the majority of the strong phos-
phorylation displayed by the 80-408 mutant.
Serine 102 is required for the effect of DDX3 on the ifnb pro-
moter. Next, we tested the interaction of our truncation and
alanine mutants with IKKε and their functionality in ifnb re-
porter gene assays. Phosphorylation of the truncation mutants
correlated with their ability to bind to IKKε. While DDX3(80 –
408) and DDX3(100 – 408) interacted with IKKε in His pull-
down assays, the DDX3(110 – 408) mutant failed to bind to
IKKε (Fig. 5A). We hypothesized that the interaction with
IKKε would be required for DDX3 to induce ifnb and therefore
tested our truncation mutants in ifnb promoter reporter gene
assays. DDX3(1– 408) enhanced IKKε-induced ifnb promoter
activation similarly to full-length DDX3 (6) (Fig. 5B). As ex-
pected from the interaction data, constructs consisting of aa
FIG 3 The N terminus of DDX3 is a direct phosphorylation target for IKKε. (A) HEK293T cells were transfected with constructs for Myc-DDX3 and 100
ng (
) or 250 ng (

) of a Flag-IKKε construct or 1,000 ng (
) or 1,800 ng (

) of a construct for a kinase-dead (KD) Flag-IKKε mutant (K38A). Cell
lysates were subjected to SDS-PAGE and WB analysis. (B to D) For in vitro kinase assays, recombinant GST-IKKε was incubated with recombinant
substrate in the presence of [-32P]ATP. Samples were then subjected to SDS-PAGE and autoradiograph analysis showing incorporation of [-32P]ATP.
Total amounts of recombinant proteins were visualized by Coomassie staining. Substrates for IKKε were full-length DDX3 or full-length IRF3 (B),
full-length His-DDX3 or the indicated His-DDX3 truncation constructs (C), or recombinant His-DDX3(1–139) or His-DDX3(5–172) or the unrelated
control protein His-Rab14 (D). (E) In vitro kinase assays were carried out as described above but in the presence of unlabeled ATP. This was followed by SDS-PAGE and
WB analysis with an anti-His antibody.
TABLE 1 Phosphopeptides identified in IT-MSMS analysis of
recombinant DDX3 or DDX3(1– 408)
Phosphorylated
residue(s)
Mascot
score Peptide sequence
Position of
peptide
Full-length DDX3
S70, S71, or S74 39 K.DKDAYSSFGSR.S 65–75
DDX3(1–408)
S152 or T156 47 R.LEQELFSGGNTGINFEK.Y 146–162
S70, S71, or S74 29 K.DKDAYSSFGSR.S 65–75
S102 or S109 28 R.GRSDYDGIGSR.G 100–110
S82, S83, or S86 12 R.GKSSFFSDR.G 80–88
a Dots indicate trypsin cleavage sites; boldface type indicates potentially phosphorylated
residues.
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110 onwards failed to enhance IKKε-induced ifnb promoter
activation, while DDX3(80 – 408) and DDX3(100 – 408) still
enhanced ifnb induction, albeit with reduced potency (Fig. 5B).
Next, we asked whether mutation of S102 in DDX3 to ala-
nine disrupts binding to IKKε. However, all our alanine mu-
tants, including the S102A mutant, interacted with IKKε in
pulldown assays (Fig. 5C). Despite this, the three mutants con-
taining the S102A substitution (the S102A, 3A, and 4A mu-
tants) failed to enhance ifnb promoter induction (Fig. 5D).
Interestingly, a phosphomimetic S102D mutant, in which ser-
ine 102 was replaced by negatively charged aspartic acid, en-
hanced IKKε-induced ifnb promoter activation similarly to
wild-type DDX3 (Fig. 5D), suggesting that phosphorylation of
this residue is indeed part of the mechanism. Because the
S102A mutant failed to enhance ifnb promoter induction, we
next investigated whether its interaction with IKKε is func-
tional. To this end, we tested the S102A mutant in kinase as-
says, which allowed us to assess its effects on IKKε and IRF3
phosphorylation. The S102A DDX3(1– 408) mutant enhanced
IKKε S172 autophosphorylation similarly to wild-type DDX3
(aa 1 to 408) (Fig. 5E, top). However, despite enhanced IKKε
activation, IRF3 phosphorylation was reduced in the presence
of the S102A mutant compared to wild-type DDX3 (Fig. 5E,
third panel). This observation made us wonder whether DDX3
has a more direct way of impacting IRF3 activation.
DDX3, but not the S102A mutant, interacts directly with
IRF3. We therefore tested whether DDX3 can directly interact
with IRF3. We used recombinant GST-tagged DDX3 to pull
down Flag-tagged IKKε or IRF3 from cell lysates. Both IKKε
and IRF3 were pulled down with DDX3 in this setup (Fig. 6A,
lanes 3 and 6, respectively). We then used recombinant GST-
tagged DDX3 or IKKε to confirm that their interaction with
IRF3 is direct. Both IKKε and DDX3 directly interacted with
recombinant His-tagged IRF3 (Fig. 6B, lanes 2 and 3, respec-
tively). Because the S102A mutant of DDX3 retained its func-
tional interaction with IKKε (Fig. 5C and E) but was impaired
with respect to IRF3 phosphorylation and ifnb promoter in-
duction (Fig. 5D and E), we next tested its interaction with
IRF3. We used His-tagged recombinant IRF3 in pulldown as-
says with ectopically expressed wild-type DDX3 or S102A
DDX3 from cell lysates. As seen before, wild-type DDX3 inter-
acted with IRF3, while, interestingly, the S102A mutant failed
to interact with IRF3 (Fig. 6C). This suggested that the defect of
the DDX3 S102A mutant might lie in an inability to interact
with IRF3. It also suggested that IRF3 and IKKε bind to a sim-
ilar region in DDX3, and we therefore used our DDX3 trunca-
tion mutants to map its IRF3 interaction site. IRF3 failed to
interact with the DDX3(100 – 408) and the DDX3(110 – 408)
mutants, while IKKε bound to the DDX3(100 – 408) mutant
but not the DDX3(110 – 408) mutant (Fig. 6D). This indicates
that IRF3 and IKKε have adjacent and potentially overlapping,
but not identical, binding sites in the N terminus of DDX3.
Next, we tested whether phosphorylation of S102 is required to
mediate IRF3 binding. To this end, we transfected HEK293T
cells with constructs for either wild-type DDX3, the phospho-
deficient S102A mutant, or the phosphomimetic S102D mu-
FIG 4 DDX3 is phosphorylated by IKKε on multiple sites. (A) Recombinant GST-IKKε was incubated with recombinant wild-type (wt) His-DDX3(1– 408) or
the indicated DDX3(1– 408) alanine mutants in the presence of [-32P]ATP. Samples were then subjected to SDS-PAGE and autoradiograph analysis. Total
amounts of His-DDX3 mutants were visualized by Coomassie staining. (B) The assay was carried out as described for panel A but using the N-terminal truncation
mutants of DDX3 as substrates. (A and B) The top panel shows results of one representative experiment out of four. For each repeat experiment, the intensity of
autoradiograph and Coomassie-stained bands was quantified using ImageJ software. Values for autoradiograph bands were normalized to the intensity of the
corresponding Coomassie-stained bands to account for differences in protein loading. The normalized signal for DDX3(1– 408) was set to 1 in each case. Data
in the lower panel are presented as means and standard deviations from four independent experiments. *, P 0.05; **, P 0.01; ***, P 0.001 [all compared
to wt DDX3(1– 408)] by an unpaired Student’s t test. (C) The assay was carried out as described for panel B but including the S102A mutant of DDX3(80 – 408).
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tant, followed by stimulation with SeV. Cell lysates were tested
for DDX3 binding to recombinant His-tagged IRF3. As seen
before, the S102A mutant failed to bind to IRF3, while wild-
type DDX3 and the phosphomimetic S102D mutant interacted
with IRF3 (Fig. 6E). Furthermore, stimulation with SeV ap-
peared to enhance binding of wild-type DDX3 to IRF3 and
treatment with the IKKε/TBK1 inhibitor BX795 (34) prevented
this effect (Fig. 6E). We concluded that S102 of DDX3 is phos-
phorylated by IKKε following SeV stimulation, which then fa-
cilitates the recruitment of IRF3 to the DDX3-IKKε complex.
To test this hypothesis further, we transfected A549 cells with
constructs for Myc-tagged DDX3 or the S102A mutant, stim-
ulated them with SeV, and immunoprecipitated Myc-tagged
DDX3/S102A. Endogenous IKKε coimmunoprecipitated with
wild-type and S102A DDX3 1 h after SeV stimulation, and the
interaction further increased up to 4 h after stimulation (Fig.
6F, top). Endogenous IRF3 was recruited to wild-type DDX3
but not the S102A mutant 4 h after SeV stimulation (Fig. 6F,
second panel). Next, we immunoprecipitated endogenous
DDX3 from A549 cells stimulated with SeV. Consistent with
the semiendogenous co-IP, IKKε coimmunoprecipitated with
endogenous DDX3 from 1 h after SeV stimulation (Fig. 6G,
top), and the DDX3-IRF3 interaction was delayed, being de-
tectable 8 h after SeV stimulation in this case (Fig. 6G, middle).
These interaction data support the sequential mechanism we
proposed, whereby IKKε is first recruited to DDX3, followed by
phosphorylation of DDX3 on S102 and subsequent recruitment of
IRF3 to the phosphorylated DDX3 (Fig. 7).
Our data therefore implicate DDX3 as a scaffolding adaptor
that links IKKε and IRF3 and coordinates their activation.
DISCUSSION
While we and others previously showed that the human DEAD
box protein DDX3 contributes to innate immune signaling path-
FIG 5 IKKε binding and serine 102 are required for the effect of DDX3 on the ifnb promoter. (A) Recombinant His-DDX3 or His-DDX3 truncation
mutants were incubated with cell lysates containing Flag-IKKε. Following pulldown, interacting proteins were subjected to SDS-PAGE and Western blot
(WB) analysis. The black border indicates images originate from the same autoradiography film and can be compared in intensity. (B) HEK293 cells were
transfected with an ifnb promoter reporter gene construct and expression constructs for Flag-IKKε and HA-DDX3 or HA-DDX3 truncations. Expression
of HA-DDX3 and Flag-IKKε was confirmed by WB analysis. Data for reporter gene assays are expressed as mean fold induction relative to control levels
and standard deviations. Shown are results of one representative experiment out of four, performed in triplicate. (C) The assay was performed as described
for panel A but using His-tagged alanine mutants of DDX3(1– 408). Black borders indicate images that originated from the same autoradiography film and
can be compared in intensity. (D) The assay was performed as described for panel B but testing full-length HA-tagged alanine mutants of DDX3. (E)
Recombinant GST-IKKε was incubated with ATP, GST-IRF3 (aa 380 to 427), and His-DDX3(1– 408) or the S102A mutant of His-DDX3(1– 408). Samples
were then subjected to SDS-PAGE and WB analysis. Phosphorylation of IKKε and IRF3 was detected with phospho-specific antibodies against pS172
(IKKε) and pS396 (IRF3).
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ways leading to IFN- induction, its exact placement in the sig-
naling pathways and mechanism of action was controversial. Our
present study elucidated the functional relevance of the interac-
tion between DDX3 and IKKε, and its role in IRF3 activation. We
show that DDX3 binds directly to IKKε and to IRF3 and contrib-
utes to their activation. In fact, strong IRF3 phosphorylation oc-
curred in an in vitro system comprising only recombinant IRF3,
IKKε, and DDX3 in the presence of ATP. The N-terminal domain
of DDX3(1– 408) was sufficient for this and its effect on the ifnb
promoter. While DDX3 enhanced IKKε autoactivation (as evi-
denced by increased phosphorylation of S172 in the activation
loop of the kinase), this was only partially responsible for the in-
creased phosphorylation of IRF3 observed in the presence of
DDX3. In this context, it is important to note that activation of
FIG 6 DDX3, but not the S102A mutant, interacts directly with IRF3. (A) Recombinant GST-DDX3 or GST was incubated with cell lysates containing
Flag-IKKε or Flag-IRF3. Following pulldown, interacting proteins were subjected to SDS-PAGE and Western blot (WB) analysis. (B) Recombinant
GST-DDX3, GST-IKKε, or GST was incubated with recombinant His-IRF3. Following pulldown, interacting proteins were subjected to SDS-PAGE and
WB analysis. (C) Recombinant His-IRF3 was incubated with cell lysates containing HA-DDX3 or HA-DDX3 S102A. Following pulldown, interacting
proteins were subjected to SDS-PAGE and WB analysis. (D) Recombinant His-DDX3 or His-DDX3 truncations were incubated with cell lysates
containing Flag-IRF3 or Flag-IKKε. Following pulldown, interacting proteins were subjected to SDS-PAGE and WB analysis. (E) HEK293T cells were
transfected with constructs for wild-type (WT), S102D, or S102A HA-DDX3. After 24 h, cells were stimulated with SeV for 2 h. BX795 was added 1 h before
SeV stimulation (50 ng/ml). Cell lysates were used for pulldowns with recombinant His-IRF3 and complexes were subjected to SDS-PAGE and WB
analysis. (F) A549 cells were transfected with constructs for either Myc-DDX3 (WT) or the Myc-DDX3 S102A mutant and stimulated with SeV as
indicated. Myc-DDX3 was immunoprecipitated (IP), followed by SDS-PAGE and WB analysis. (G) A549 cells were stimulated with SeV for the indicated
length of time; cell lysates were then subjected to IP with an anti-DDX3 antibody, followed by SDS-PAGE and WB analysis. (A, B, and D) Black borders
indicate images originating from the same autoradiography film, which can be compared in intensity.
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IKKε or TBK1 is not sufficient for activation of IRF3 in cells but
that an additional adaptor is required for linking the activated
kinases to IRF3 (17, 35). TRAF3 (TNF receptor-associated factor
3) was suggested as a candidate for this role, as it is required for
IRF3 but not TBK1/IKKε activation (35). Also, in a recent study,
the adaptor molecule STING, which facilitates signaling down-
stream of DNA receptors, was shown to link TBK1 to IRF3 (36).
Interestingly, the effects of STING on TBK1 and IRF3 strongly
resemble the effects we describe here for DDX3, IKKε, and IRF3.
STING also mediated TBK1 and IRF3 activation in an in vitro
reconstitution system that is essentially identical to our experi-
mental setup (36). Interestingly, both DDX3 and STING had dis-
tinct effects on IKKε and IRF3 activation.
Effect of DDX3 on IKK activation. With respect to its mech-
anism for enhancing IKKε activation, we have shown that DDX3
interacts with the scaffolding/dimerization domain (SDD) of
IKKε (aa 383 to 647) and not with the C-terminal region (aa 684 to
716) that mediates binding to NAP1, TANK, and Sintbad. These
adaptor proteins have also been shown to be involved in activation
of TBK1 and IKKε downstream of PRRs (28). However, as they
interact with a different region of IKKε, they appear to have a
distinct mode of action compared to DDX3 (29, 30). It was sug-
gested that they might recruit TBK1/IKKε to distinct subcellular
locations for activation (29).
In the recently solved crystal structure of IKK, a kinase that is
closely related to IKKε, the SDD forms an elongated -helical
region (37). The SDD mediates dimerization of the kinase and
might contribute to substrate specificity. Based on their structure,
the authors concluded that autophosphorylation of the activation
loop could not occur within a single IKK dimer but was more
likely to be mediated by a second IKK dimer in a transautophos-
phorylation event. Thus, higher-order arrangements of IKK
might be required for autophosphorylation (37). It is expected
that TBK1 and IKKε display a domain structure similar to that of
IKK. Indeed, recent biochemical evidence suggests that TBK1 is
activated in a similar transautophosphorylation event requiring
the juxtaposition of two TBK1 dimers for phosphorylation of
S172 (38). These studies suggest that a critical event for activation
of the IKKs and IKK-related kinases is the positioning of kinase
dimers in a conformation that allows for their transautophospho-
rylation.
Through its interaction with the SDD of IKKε, DDX3 could
potentially stabilize such arrangements of IKKε dimers and
thereby support efficient transautophosphorylation. Further bio-
chemical studies will be required to confirm whether DDX3 in-
deed supports the formation of such higher-order IKKε com-
plexes.
DDX3 also weakly interacted with the kinase domain of IKKε.
This is likely because DDX3 is also a phosphorylation substrate of
IKKε and therefore has to transiently interact with its kinase do-
main.
Phosphorylation of DDX3 by IKK. Our data provide strong
evidence that the N-terminal tail region of DDX3 is phosphory-
lated directly by IKKε. DDX3 has previously been identified as an
interaction partner and phosphorylation target of TBK1 (7). Sev-
eral TBK1 phosphorylation sites were identified within DDX3;
however, most of these were located within the two RecA-like
globular domains of DDX3, and none mapped to the N-terminal
tail of DDX3 (7). In our hands, both the N-terminal (aa 1 to 408)
and C-terminal (aa 409 to 662) domains of DDX3 interacted
with IKKε, but only the N-terminal domain was strongly phos-
phorylated (Fig. 3C). It is likely that TBK1 and IKKε phosphor-
ylate the same or at least overlapping residues in DDX3, and we
showed that TBK1 can phosphorylate the isolated N terminus
of DDX3 (aa 5 to 172) to a degree similar to that exhibited by
IKKε (Fig. 3E). The published TBK1 phosphorylation sites
were determined using a peptide array (7), and it is possible
that specificity of phosphorylation differs in the context of
larger protein domains. However, we also detected an interac-
tion of IKKε with the C-terminal domain of DDX3 (aa 409 to
662) as well as weak phosphorylation of this domain by IKKε. It
is therefore possible that the C terminus of DDX3 also contains
veritable IKKε phosphorylation sites.
Here, we show that the N-terminal tail region of DDX3 that is
required for ifnb induction undergoes strong phosphorylation by
IKKε. Our N-terminal truncation mutants revealed the region
between aa 100 and 110 of DDX3 as an IKKε binding site and
serine 102 as a functionally important IKKε phosphorylation site.
In addition, our mass spectrometry analysis and alanine substitu-
tion mutants suggested that there are multiple other phosphory-
lation sites for IKKε within the N terminus of DDX3, including
S71, S82 or S83, and S152. It is not unusual for IKKε to phos-
phorylate several clustered serine residues. In IRF3, it phos-
phorylates at least seven serine residues within two C-terminal
clusters (39). It is possible that some of these phosphorylation
events are interdependent in that phosphorylated serine resi-
dues prime for subsequent phosphorylation of nearby serine
residues. This interdependency could explain the significant
FIG 7 DDX3 acts as a scaffolding adaptor for IKKε and IRF3. Our model for the sequential mechanism by which DDX3 facilitates IKKε (1) and IRF3 (2)
activation is depicted here. DDX3 first recruits IKKε, which stimulates IKKε autophosphorylation and activation. In this step, the N-terminal tail of DDX3 is
phosphorylated by IKKε on multiple sites, including serine 102. The phosphorylation of S102 mediates recruitment of IRF3 to the DDX3-IKKε complex. IRF3
can subsequently be phosphorylated by IKKε and then contributes to ifnb promoter activation. On the right, the process is shown for the DDX3 mutant lacking
S102. In this case, the physical and functional interaction with IKKε proceeds normally (1). However, due to the lack of S102 phosphorylation, IRF3 is not
recruited to DDX3 and its phosphorylation is disrupted (2).
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reductions in phosphorylation we observed with our single-
alanine-substitution mutants. On the other hand, we were un-
able to fully abrogate phosphorylation of DDX3 by IKKε with
our quadruple-alanine mutant (4A 1– 408 mutant), suggesting
that there might be further IKKε phosphorylation sites in the N
terminus of DDX3.
In order to identify functionally important IKKε phosphory-
lation sites, we tested our alanine substitution mutants in ifnb
reporter gene assays. S71 most closely matches the IKKε consen-
sus sequence determined by Hutti et al. and was also the only
phosphopeptide we identified in our mass spectrometry analysis
with full-length DDX3. However, phosphorylation of the 80 – 408
truncation mutant was only slightly reduced compared to that of
full-length DDX3, and mutation of S71 to alanine did not affect
the ability of DDX3 to enhance IKKε-mediated ifnb promoter
activation. We were initially also particularly interested in S82 and
S83, as these are in the region of DDX3 that is targeted by its VACV
antagonist K7. We had previously shown that mutation of the
adjacent double phenylalanine motif (F84 and F85) abrogated the
effect of DDX3 on the ifnb promoter (19). And while the S82,83A
(2A) mutant displayed reduced phosphorylation by IKKε and
phosphorylation of the 100 – 408 construct was also reduced
compared to the 80 – 408 construct, the 2A mutant had no ap-
parent defect with respect to ifnb promoter induction. It is
possible that the phosphorylation of S71, S83, S82, and S152 by
IKKε has subtle effects on ifnb induction that we failed to de-
tect, or that there is functional redundancy between these res-
idues. It is also possible that the phosphorylation of these res-
idues in DDX3 affects cellular processes unrelated to ifnb
induction. We observed increased DDX3 protein levels in the
presence of IKKε (Fig. 3A); thus, it is possible that DDX3 phos-
phorylation by IKKε increases its stability.
In this study, we focused on serine 102 of DDX3, because the
phosphodeficient S102A mutant, but not a phosphomimetic
S102D mutant, failed to mediate ifnb promoter activation. This
demonstrated that phosphorylation of S102 in DDX3 by IKKε is
required for ifnb induction. The S102A mutant still interacted
with IKKε and enhanced its autophosphorylation, but its ability to
enhance IRF3 phosphorylation was reduced compared to that of
wild-type DDX3 (Fig. 5E). This suggested to us that DDX3 might
affect IRF3 activation more directly.
Effect of DDX3 on IRF3 activation. We show here that DDX3
directly interacts with IRF3. Interestingly, phosphorylation of
DDX3 at S102 by IKKε appeared to increase the affinity of DDX3
for IRF3: the phosphodeficient S102A mutant did not interact
with IRF3, while the phosphomimetic S102D mutant did (Fig.
6E). Stimulation with SeV increased the interaction between
DDX3 and IRF3, which was prevented by the IKKε/TBK1 inhibi-
tor BX795 (Fig. 6E). This provided evidence that DDX3 has to be
phosphorylated by IKKε before it can bind to IRF3. Results from
our coimmunoprecipitation experiments support this sequence
of events: after SeV stimulation, IKKεwas recruited to DDX3 first,
followed by delayed IRF3 binding (Fig. 6F and G).
The failure of the S102A mutant to induce ifnb promoter acti-
vation suggests that the phosphorylation-induced interaction be-
tween DDX3 and IRF3 is critical for ifnb induction. We also dem-
onstrate here that IKKε and IRF3 have immediately adjacent
binding sites in the N-terminal region of DDX3 (Fig. 6D). We
therefore propose a model whereby IKKε-mediated phosphoryla-
tion of serine 102 in DDX3 facilitates recruitment of IRF3 to
DDX3. This recruitment is required for efficient IRF3 phosphor-
ylation by IKKε, which is possibly facilitated by their juxtaposition
when bound to DDX3 (Fig. 7).
DDX3 and STING act as adaptors that link activated IKK-
related kinases to IRF3. As mentioned above, the protein STING
has also recently been shown to facilitate IRF3 phosphorylation by
TBK1. STING is required for IRF3 activation and ifnb induction
downstream of cytosolic DNA receptors (40). There are intriguing
parallels between the effects of STING on TBK1 and IRF3, as re-
ported by Tanaka and Chen (36), and the effects of DDX3 on IKKε
and IRF3 we demonstrate here. STING also enhanced both TBK1
autophosphorylation and IRF3 phosphorylation in an in vitro re-
constitution system. Intriguingly, for both STING and DDX3, the
effects on TBK1/IKKε and IRF3 activation could be uncoupled by
a serine-to-alanine mutation. Mutations to Ser366 (or Leu374) in
STING disrupted its effect on IRF3 activation but not on TBK1
activation (36). This is strongly reminiscent of our data for the
DDX3 S102A mutant. While Tanaka and Chen found no direct
evidence that S366 of STING is phosphorylated by TBK1 but sug-
gested that STING phosphorylation by TBK1 strengthens its in-
teraction with IRF3 (36), we demonstrate here that S102 of DDX3
is directly phosphorylated by IKKε and that this phosphorylation
mediates IRF3 binding.
It thus appears that STING and DDX3 employ very similar
mechanisms for coordinating activation of the IKK-related ki-
nases and IRF3. As mentioned above, it recently emerged that an
additional adaptor is required for linking the activated IKK-re-
lated kinases to IRF3 in cells (34). Both STING and DDX3 appear
to be able to carry out this function. In addition to this, both of
them also enhance the upstream activation of the IKK-related
kinases. These two functions are distinct, because they can be un-
coupled by point mutations in DDX3 (S102A) and STING. This
suggests that it might be possible to target the DDX3-IRF3 inter-
action interface surrounding S102 therapeutically for blocking ex-
cess IFN production while leaving other IKKε- and DDX3-medi-
ated cellular functions intact.
In summary, our study has identified a novel direct interaction
between DDX3 and IRF3 that is regulated by IKKε phosphoryla-
tion of DDX3 and critical for ifnb induction. Our data implicate
DDX3 as a bridging adaptor for IKKε and IRF3 in the RLH path-
way, reminiscent of the suggested role for STING in DNA receptor
pathways. It is therefore possible that STING and DDX3 belong to
a group of functionally related scaffolding adaptors that coordi-
nate activation of the IKK-related kinases and IRF3 in different
signaling pathways. It will be interesting to see whether more pro-
teins are identified that employ a similar sequential mechanism
for the coordinated activation of IKKε/TBK1 and IRF3.
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